Andolast

Drug Profile

Andolast

Alternative Names: CR 2039; Diazolast

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Antiallergics; Antiasthmatics; Benzamides; Small molecules; Tetrazoles
  • Mechanism of Action Calcium-activated potassium channel openers; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Aug 2015 Phase-III development is ongoing in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in Italy
  • 23 Oct 2014 Phase III development is ongoing in Allergic rhinitis, Asthma and Chronic obstructive pulmonary disease in Italy
  • 10 Oct 2014 Rottapharm Madaus has been acquired by Meda
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top